Market Size of Small Molecule Drug Discovery Industry
Study Period | 2019 - 2029 |
Market Size (2024) | USD 56.94 Billion |
Market Size (2029) | USD 86.65 Billion |
CAGR (2024 - 2029) | 8.76 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Small Molecule Drug Discovery Market Analysis
The Small Molecule Drug Discovery Market size is estimated at USD 56.94 billion in 2024, and is expected to reach USD 86.65 billion by 2029, growing at a CAGR of 8.76% during the forecast period (2024-2029).
Factors such as the rise in demand for small-molecule drugs, an increasing number of contract organizations for research and development, rising funding activities for research and development of small-molecule therapeutics, and increasing usage of small molecules in treating chronic diseases are expected to drive the market's growth.
Small molecule drugs are extensively used in the treatment of chronic diseases. The increasing prevalence of these chronic diseases is expected to drive the market's growth. For instance, according to the World Heart Report 2023, more than half a billion people worldwide were affected by cardiovascular diseases in 2022. According to the American Cancer Society stats for 2024, 2 million new cancer cases are projected to occur in the United States, an increase from 1.9 million cases in 2023. Such an increase in chronic diseases increases the demand for the discovery of new small molecules to manage chronic diseases more effectively. Hence, the rising prevalence of chronic diseases is expected to drive the small molecule drug discovery market during the forecast period.
The increasing research and development funding for discovering small molecules is also expected to drive the market. For instance, in order to harness the power of artificial intelligence (AI) for small molecule drug discovery, Sanofi entered a USD 140 million multi-year research collaboration with French pharmacy company Aqemia. The collaboration is poised to help reshape the landscape of drug development and improve the way new small-molecule therapeutic compounds are identified and optimized. Hence, the increasing funding activities in small molecule drug discovery are expected to drive the market.
The launch of technologically advanced products and partnerships by the market players are expected to propel the growth of the market. For instance, in July 2022, Dotmatics, one of the leaders in the research and development of scientific software connecting science, data, and decision-making, released a small-molecule drug discovery solution. It is an integrated scientific research and development platform with pre-configured workflows and expanded data management capabilities. In April 2022, Iktos and Teijin Pharma Limited signed a strategic collaboration agreement in artificial intelligence for new drug design. As per the agreement, Iktos generative modeling technology will be implemented and applied to several of Teijin Pharma's small molecule drug discovery projects to expedite the identification of potential pre-clinical candidates. Such launches and partnerships are expected to contribute to the growth of the market.
Factors such as the rising demand for small molecules in treating chronic diseases and increasing funding for small-molecule drug discovery are driving the growth of the market. However, high drug development costs and stringent regulatory scenarios are expected to restrain market growth.
Small Molecule Drug Discovery Industry Segmentation
As per the report's scope, small molecule drug discovery represents all the costs incurred by a drug discovery company during the discovery phase. A small molecule is a substance that can enter cells quickly as it has a low molecular weight. These are used as drugs for therapeutic purposes and include chemically synthesized drug molecules and all biologically synthesized drug molecules.
The small molecule drug discovery market is segmented by therapeutic area, process/phase, and geography. By therapeutic area, the market is segmented into oncology, central nervous system, cardiovascular, respiratory, metabolic disorders, gastrointestinal, and other therapeutic areas. By process/phase, the market is segmented into target ID/validation, hit generation and selection, lead identification, and lead optimization. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for all the above segments.
By Therapeutic Area | |
Oncology | |
Central Nervous System | |
Cardiovascular | |
Respiratory | |
Metabolic Disorders | |
Gastrointestinal | |
Other Therapeutic Areas |
By Process/Phase | |
Target ID/Validation | |
Hit Generation and Selection | |
Lead Identification | |
Lead Optimization |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Small Molecule Drug Discovery Market Size Summary
The small molecule drug discovery market is poised for significant growth, driven by the increasing demand for small-molecule drugs and their application in treating chronic diseases. The market is experiencing a surge in activity due to the rising prevalence of conditions such as cancer and cardiovascular diseases, which necessitate the development of effective therapeutics. The COVID-19 pandemic further accelerated research in this sector, as global efforts focused on identifying and repurposing small molecules to combat the virus, thereby expanding the therapeutic options available. Technological advancements, particularly in artificial intelligence and computational tools, are playing a crucial role in enhancing the efficiency of drug discovery processes, from target identification to lead optimization. Strategic partnerships and collaborations among key industry players are also contributing to the market's expansion, as they facilitate the development and deployment of innovative drug discovery solutions.
North America currently leads the small molecule drug discovery market, supported by a high incidence of chronic diseases and a favorable regulatory environment for new drug approvals. The region's dominance is further bolstered by strategic initiatives such as research collaborations and the introduction of advanced drug discovery platforms. Despite the market's moderate nature, characterized by the presence of both global and regional players, the competitive landscape is marked by the activities of major companies like Pfizer Inc., Bristol-Myers Squibb Company, and Merck KGaA. These companies, along with others, are actively engaged in expanding their portfolios and enhancing their capabilities through technological innovations and strategic partnerships. As the demand for small-molecule drugs continues to rise, the market is expected to witness sustained growth, driven by ongoing research and development efforts and the increasing burden of chronic diseases worldwide.
Small Molecule Drug Discovery Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rise in Demand for Small Molecule Drugs
-
1.2.2 Increasing Number of Contract Organizations for R&D
-
1.2.3 Small Molecules in Treatment of Chronic Diseases
-
-
1.3 Market Restraints
-
1.3.1 High Drug Development Costs
-
1.3.2 Strict Regulations
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD)
-
2.1 By Therapeutic Area
-
2.1.1 Oncology
-
2.1.2 Central Nervous System
-
2.1.3 Cardiovascular
-
2.1.4 Respiratory
-
2.1.5 Metabolic Disorders
-
2.1.6 Gastrointestinal
-
2.1.7 Other Therapeutic Areas
-
-
2.2 By Process/Phase
-
2.2.1 Target ID/Validation
-
2.2.2 Hit Generation and Selection
-
2.2.3 Lead Identification
-
2.2.4 Lead Optimization
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Small Molecule Drug Discovery Market Size FAQs
How big is the Small Molecule Drug Discovery Market?
The Small Molecule Drug Discovery Market size is expected to reach USD 56.94 billion in 2024 and grow at a CAGR of 8.76% to reach USD 86.65 billion by 2029.
What is the current Small Molecule Drug Discovery Market size?
In 2024, the Small Molecule Drug Discovery Market size is expected to reach USD 56.94 billion.